ESAs: A lesson in labelling transparency
This article was originally published in Scrip
Executive Summary
News that the US FDAhas ordered safety-related labelling changes for erythropoiesis-stimulating agents made headlines last week. However, the manner in which the FDA disclosed the action could have significant ramifications for the pharmaceutical industry, particularly companies that disagree with the agency's labelling directives.